Recombinant Human BAI2 Protein Fc Chimera, CF

WhenRecombinant Human C1qL3 (Catalog # 9115-TN) is coated at 2 µg/mL (100 μL/well), Recombinant Human BAI2 FcChimera (Catalog # 9338-BA) binds with an ED50 of25-150 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BAI2 Protein Fc Chimera, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human C1qL3 (Catalog # 9115-TN) is immobilized at 2 μg/mL, 100 μL/well, the concentration of Recombinant Human BAI2 Fc Chimera that produces 50% of the optimal binding response is approximately 25-150 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human BAI2 protein
  

  Human BAI2 (Phe21-Asp911 ) Accession # O60241-3	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O60241-3
• N-terminal Sequence: Phe21
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 123 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 128-200 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BAI2 Protein Fc Chimera, CF

• BAI2
• brain-specific angiogenesis inhibitor 2
• Brain-specific angiongenesis inhibitor-2

Background

Brain angiogenesis inhibitor 2 (BAI2), along with BAI1 and BAI3, form a subfamily of brain specific adhesion GPCRs. They are large, glycosylated molecules, approximately 180-220 kDa, and play a role in neuronal synapse formation and maintenance. Mature human BAI2 consists of a 903 amino acid (aa) N-terminal extracellular domain (ECD) containing four TSP1 domains, a hormone binding domain (HBD), a GAIN domain and a GPS protease sensitive linker, followed by a region with seven transmembrane segments and a 410 aa C-terminal cytoplasmic domain (1). Within the N-terminal ECD, human BAI2 shares 96% aa sequence identity with both mouse and rat BAI2. BAI2 is expressed primarily in neurons and astrocytes of the hippocampus and cerebral cortex in the brain (2, 3). To become functional, BAI2 might require activation by cleavage at the GPS domain (4). BAI family members are known to bind the C1q-like complement (C1qL) family via thrombospondin type 1 repeats (TSRs) which are conserved between BAI members (5). BAI2 has been shown to suppress expression of VEGF leading to increased neurogenesis in the dentate gyrus of the hippocampus (6).

1. Duman, J.G. et al. (2016) Neural Plast. 2016:8301737.
2. Shiratsuchi, T. et al. (1997) Cytogenet. Cell Genet. 79:103.
3. Kee, H.J. et al. (2002) J. Cereb. Blood Flow Metab. 22:1054.
4. Daisuke, O. et al. (2010) J. Recept Signal Transduct Res 30:143.
5. Bolliger, M.F. et al. (2011) Proc. Natl. Acad. Sci. USA 108:2534.
6. Jeong, B.C. et al. (2016) FEBS Lett 580:669.

Bioinformatics

• Uniprot:
  • O60241-3()